Domov › Obézita › New York

Klinické štúdie Obézita v štáte New York

75 štúdií pre Obézita hľadá účastníkov v zariadeniach v štáte New York.

Mestá v štáte New York

Oficiálny text štúdie (anglicky)

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

Rochester Clinical Research /ID# 282484, Rochester

Prebieha náborFáza 2

Vek 18 až 75 · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT07752979

Hydration Intervention to Decrease Side Effects Associated With GLP - 1 RA Therapy

State University of New York at Buffalo, South Campus, Buffalo

Prebieha nábor

Vek 18 až 60 · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT07641361

Comparing the Efficacy and Safety of the EndoZip System and Apollo ESG in Obese Patients

Weill Cornell -1300 York Avenue, New York
Lenox Hill Hospital | Northwell Health, New York

Prebieha nábor

Vek 21 až 65 · Všetky pohlavia · Aktualizované 1. 10. 2026 · NCT07090005

A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event

Rochester Clinical Research - Buffalo, Buffalo
CHEAR Center LLC, The Bronx

Prebieha náborFáza 2

Vek 18 a viac · Všetky pohlavia · Aktualizované 30. 9. 2026 · NCT07783802

AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

Southgate Medical Group, LLP, West Seneca

Prebieha náborFáza 3

Vek 18 a viac · Všetky pohlavia · Aktualizované 30. 9. 2026 · NCT07533175

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

UBMD Physicians Group - Pediatrics - Conventus, Buffalo
SUNY Upstate Medical Univ - Syracuse, Syracuse
Advantage Clinical Trials, The Bronx

Prebieha náborFáza 3

Vek 8 až 18 · Všetky pohlavia · Aktualizované 30. 9. 2026 · NCT07253285

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

Rochester Clinical Research, Rochester

Prebieha náborFáza 2

Vek 18 a viac · Všetky pohlavia · Aktualizované 29. 9. 2026 · NCT07685808

Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss

ALSA Research-Manhattan, New York

Prebieha náborFáza 2

Vek 18 až 75 · Všetky pohlavia · Aktualizované 28. 9. 2026 · NCT07837973

AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

Comprehensive Weight Ctrl Prog, New York

Prebieha náborFáza 3

Vek 18 a viac · Všetky pohlavia · Aktualizované 28. 9. 2026 · NCT07720271

A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

Ichor Research, Syracuse
Southgate Medical Group, LLP, West Seneca

Prebieha náborFáza 3

Vek 18 a viac · Všetky pohlavia · Aktualizované 28. 9. 2026 · NCT07668414

A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

Weill Cornell Medicine - Comprehensive Weight Control Center, New York
Rochester Clinical Research, LLC, Rochester

Prebieha náborFáza 3

Vek 18 a viac · Všetky pohlavia · Aktualizované 28. 9. 2026 · NCT07595549

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

New York Gastroenterology Associates, New York
Care Access - Yonkers, Yonkers

Prebieha náborFáza 3

Vek 18 až 70 · Všetky pohlavia · Aktualizované 24. 9. 2026 · NCT06937099

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

UBMD Pediatrics, Buffalo

Prebieha náborFáza 3

Vek 6 až 17 · Všetky pohlavia · Aktualizované 24. 9. 2026 · NCT06672549

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Icahn School of Medicine at Mount Sinai, New York
New York Gastroenterology Associates, New York
Care Access - Yonkers, Yonkers

Prebieha náborFáza 3

Vek 18 až 70 · Všetky pohlavia · Aktualizované 24. 9. 2026 · NCT06937086

AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight

New York Gastroenterology Associates, New York

Prebieha náborFáza 3

Vek 18 a viac · Všetky pohlavia · Aktualizované 24. 9. 2026 · NCT07339423

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

NYC Research INC, Long Island City

Prebieha náborFáza 3

Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT07282600

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

NYU Langone Health, New York
Weill Cornell Medical College, New York
IMA Clinical Research Manhattan, New York

Prebieha náborFáza 3

Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT07392190

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Rochester Clinical Research - Buffalo, Buffalo

Prebieha náborFáza 3

Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT07369011

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

Velocity Clinical Research - Binghamton, Binghamton
Hudson Valley Cardiovascular Practice PC, Poughkeepsie
Rochester Clinical Research, Rochester
a 2 ďalších

Prebieha náborFáza 3

Vek 45 až 99 · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT07037433

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

Rochester Clinical Research, LLC, Rochester

Prebieha náborFáza 3

Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT07321886

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

Ellipsis Research Group - Brooklyn - 7th Street, Brooklyn
Rochester Clinical Research - Buffalo, Buffalo
NYC Research INC, Long Island City
a 1 ďalších

Prebieha náborFáza 3

Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT07353931

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

Dent Neurologic Institute, Amherst
Rochester Clinical Research, LLC, Rochester

Prebieha náborFáza 2

Vek 18 až 75 · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT07589608

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

AURORA-1 Clinical Site, New Windsor

Prebieha náborFáza 3

Vek 18 a viac · Všetky pohlavia · Aktualizované 16. 9. 2026 · NCT07743463

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

AURORA-2 Clinical Site, East Northport
AURORA-2 Clinical Site, East Syracuse
AURORA-2 Clinical Site, New Windsor

Prebieha náborFáza 3

Vek 18 a viac · Všetky pohlavia · Aktualizované 16. 9. 2026 · NCT07743450

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

Capital Cardiology Associates, Albany
Icahn School of Medicine at Mount Sinai, New York
Hudson Valley Cardiovascular Practice PC, Poughkeepsie
a 1 ďalších

Prebieha náborFáza 3

Vek 18 až 99 · Všetky pohlavia · Aktualizované 16. 9. 2026 · NCT07037459

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

NYC Research INC, Long Island City
Richmond University Medical Center, Staten Island
Southgate Medical Group, West Seneca

Prebieha náborFáza 2

Vek 18 až 75 · Všetky pohlavia · Aktualizované 14. 9. 2026 · NCT06897475

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

Rochester Clinical Research, Buffalo

Prebieha náborFáza 3

Vek 18 a viac · Všetky pohlavia · Aktualizované 14. 9. 2026 · NCT07351045

AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

Weil Cornell Medicine, New York

Prebieha náborFáza 3

Vek 18 a viac · Všetky pohlavia · Aktualizované 11. 9. 2026 · NCT07571005

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

ACCOMPLISH-2 Research Site, Albany
ACCOMPLISH-2 Research Site, Albany
ACCOMPLISH-2 Research Site, Brooklyn
a 1 ďalších

Prebieha náborFáza 3Vítaní zdravých dobrovoľníkov

Vek 18 až 79 · Všetky pohlavia · Aktualizované 11. 9. 2026 · NCT07654374

AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

Weil Cornell Medicine, New York

Prebieha náborFáza 3

Vek 18 a viac · Všetky pohlavia · Aktualizované 9. 9. 2026 · NCT07571109

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Dent Neurologic Institute, Amherst
Velocity Clinical Research, Syracuse, East Syracuse
Rochester Clinical Research, LLC, Rochester

Prebieha náborFáza 2

Vek 18 až 75 · Všetky pohlavia · Aktualizované 8. 9. 2026 · NCT06143956

Graded Insulin Suppression Test P&F

Columbia University Irving Medical Center, New York

Prebieha náborFáza 1Vítaní zdravých dobrovoľníkov

Vek 18 až 65 · Všetky pohlavia · Aktualizované 8. 9. 2026 · NCT06592261

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

Equity Medical, New York

Prebieha náborFáza 4

Vek 18 a viac · Všetky pohlavia · Aktualizované 4. 9. 2026 · NCT06857942

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

Kailera Clinical Site, Albany
Kailera Clinical Site, Laurelton
Kailera Clinical Site, New York

Prebieha náborFáza 3

Vek 18 a viac · Všetky pohlavia · Aktualizované 3. 9. 2026 · NCT07284901

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

Velocity Clinical Research- Binghamton, Binghamton
Rochester Clinical Research, Rochester

Prebieha náborFáza 3

Vek 18 až 99 · Všetky pohlavia · Aktualizované 3. 9. 2026 · NCT07684235

Alpelisib Challenge Test (ACT)

Columbia University Irving Medical Center, New York

Prebieha náborFáza 1Vítaní zdravých dobrovoľníkov

Vek 18 až 70 · Všetky pohlavia · Aktualizované 3. 9. 2026 · NCT07778524

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

Kailera Clinical Site, Rochester

Prebieha náborFáza 3

Vek 18 a viac · Všetky pohlavia · Aktualizované 3. 9. 2026 · NCT07284875

Taxi ROADmAP (Realizing Optimization Around Diet And Physical Activity)

Mexican Consulate's Ventanilla de Salud (VDS), New York

Prebieha náborFáza 2Vítaní zdravých dobrovoľníkov

Vek 21 a viac · Všetky pohlavia · Aktualizované 2. 9. 2026 · NCT05770570

Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

Kailera Clinical Site, Albany

Prebieha náborFáza 3

Vek 18 a viac · Všetky pohlavia · Aktualizované 1. 9. 2026 · NCT07284979

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

Icahn School of Medicine at Mount Sinai, New York
Rochester Clinical Research, Rochester

Prebieha náborFáza 3

Vek 18 až 99 · Všetky pohlavia · Aktualizované 27. 8. 2026 · NCT07575399

Z ClinicalTrials.gov, dáta načítané 5. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.